News

2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
Resverlogix Completes Enrollment of Phase 2 Clinical Trial of RVX-208 in Patients with Pre-Diabetes Mellitus
Resverlogix Announces Two New Findings from the ASSURE Trial Relating to Inflammation and Plaque Vulnerability
Resverlogix Announces Voting Results
Further Analysis of the ASSURE Data Finds a Responder Group for RVX-208 with Statistically Significant Regression of Coronary Atherosclerosis
Resverlogix Announces a Corporate Update Conference Call & Webcast
Resverlogix Closes $1.6 million Private Placement
Resverlogix Announces $1.6 million Private Placement
Resverlogix to host Conference Call & Webcast with Q&A
Resverlogix Reports Top-Line Results from ASSURE Clinical Trial
Resverlogix Corp. announces completion of spin-out transaction
Zenith Epigenetics Corp. commences operations
Resverlogix Corp. shareholders approve plan of arrangement
Resverlogix Announces Details of Anticipated Distribution of Newco Shares
Resverlogix's Board Approves Arrangement to Spin-Out RVX Therapeutics Inc. and Confirms Special Meeting of Shareholders
Resverlogix Completes Dosing In ASSURE Clinical Trial
Resverlogix to Spin-out RVX Therapeutics Inc. to Shareholders
Resverlogix Secures Increase to Citibank Loan to $38.8 million
Resverlogix comments on steady climb of share price